Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 25, 2026, 10:33 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 865–888 of 3,665 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: sample collection Clear all
Not yet recruiting Not applicable Interventional

Web-based Lifestyle Program, mHealth and EMA Intervention, to Improve Weight Loss in Rural Stage I-III Postmenopausal Breast and Endometrial Cancer Survivors, HERO-C Trial

NCT07723235
View directory record Official record
Conditions
Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8, Endometrial Carcinoma, Stage I Uterine Corpus Carcinoma or Carcinosarcoma AJCC v8, Stage II Uterine Corpus Carcinoma or Carcinosarcoma AJCC v8, Stage III Uterine Corpus Carcinoma or Carcinosarcoma AJCC v8
Interventions
Aerobic Exercise, Biospecimen Collection, Dietary Intervention, Discussion, Goal Setting, Internet-Based Intervention, Medical Device Usage and Evaluation, Questionnaire Administration, Resistance Training, Smartphone Application-based Intervention, Supportive Care, Tailored Intervention
Other · Procedure · Behavioral
Lead sponsor
Ohio State University Comprehensive Cancer Center
Other
Eligibility
40 Years to 69 Years · Female only
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Jul 23, 2026 · Synced Oct 25, 2026, 10:33 PM EDT
Enrolling by invitation No phase listed Observational Accepts healthy volunteers

Specimen and Data Collection for a Novel Biomarker Combination for the Differential Diagnosis of Inflammatory Bowel Disease and Irritable Bowel Syndrome.

NCT07471490
View directory record Official record
Conditions
IBD (Inflammatory Bowel Disease), IBS (Irritable Bowel Syndrome), Gastrointestinal Symptoms
Interventions
Not listed
Lead sponsor
DiaSorin Inc.
Industry
Eligibility
2 Years and older
Enrollment
300 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Mar 13, 2026 · Synced Oct 25, 2026, 10:33 PM EDT
Completed No phase listed Observational

A New Reagent Assay Examining Natural Parvovirus B19 Infection in Sickle Cell Disease

NCT02261480
View directory record Official record
Conditions
Sickle Cell Disease
Interventions
Blood draw, Nasopharyngeal wash
Other
Lead sponsor
St. Jude Children's Research Hospital
Other
Eligibility
1 Year and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Sep 19, 2016 · Synced Oct 25, 2026, 10:33 PM EDT
Completed No phase listed Observational

Colvera for Detection of Disease Recurrence

NCT03706235
View directory record Official record
Conditions
Colorectal Adenocarcinoma
Interventions
Blood draw (venipuncture)
Other
Lead sponsor
Clinical Genomics Pathology
Industry
Eligibility
18 Years and older
Enrollment
488 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
12
States / cities
Redondo Beach, California • Dover, Delaware • Chicago, Illinois + 9 more
Source: ClinicalTrials.gov public record
Updated Jul 14, 2020 · Synced Oct 25, 2026, 10:33 PM EDT
Recruiting Not applicable Interventional

Effect of Prenatal and Postnatal Intervention Strategies on Breastfeeding Outcomes in Women With Excessive Weight (Ready, Set, Nourish Study)

NCT06929091
View directory record Official record
Conditions
Breastfeeding, Dietary Intervention, Milk Expression, Breast
Interventions
Lactation Support and ABME, Lactation Support and meal plan, Lactation Support
Other
Lead sponsor
Arkansas Children's Hospital Research Institute
Other
Eligibility
18 Years and older · Female only
Enrollment
240 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
1
States / cities
Little Rock, Arkansas
Source: ClinicalTrials.gov public record
Updated Sep 24, 2026 · Synced Oct 25, 2026, 10:33 PM EDT
Terminated No phase listed Observational

Internet-Based Clinical Information and Blood Sample Collection From Patients With Non-Small Cell Lung Cancer Who Never Smoked Cigarettes

NCT01141218
View directory record Official record
Conditions
Lung Cancer
Interventions
internet-based protocol and physician referral
Other
Lead sponsor
Vanderbilt-Ingram Cancer Center
Other
Eligibility
18 Years and older
Enrollment
88 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Apr 25, 2017 · Synced Oct 25, 2026, 10:33 PM EDT
Completed Not applicable Interventional Results available

Utility of Placental/Umbilical Cord Blood in Early Onset Neonatal Sepsis in Very Low Birth Weight Infants

NCT03694613
View directory record Official record
Conditions
Preterm Infant, Early-Onset Neonatal Sepsis, Umbilical Cord
Interventions
Placental/Umbilical Cord Blood sample
Other
Lead sponsor
The University of Texas Medical Branch, Galveston
Other
Eligibility
Up to 1 Day
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Galveston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 10, 2021 · Synced Oct 25, 2026, 10:33 PM EDT
Active, not recruiting No phase listed Observational

Assessing Chest Pain Using Point-of-Care High-Sensitivity Troponin I in the Emergency Department

NCT06899776
View directory record Official record
Conditions
ACS (Acute Coronary Syndrome)
Interventions
Abbott i-STAT point of care (POC) device
Device
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years and older
Enrollment
600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
3
States / cities
Charlotte, North Carolina • High Point, North Carolina • Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Jul 29, 2026 · Synced Oct 25, 2026, 10:33 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Evaluation of the Atlas Genetics io® CTNG System

NCT03071510
View directory record Official record
Conditions
Chlamydia Trachomatis, Gonorrhea
Interventions
Atlas Genetics io® system
Device
Lead sponsor
Binx Health Limited
Industry
Eligibility
14 Years and older
Enrollment
7,128 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2019
U.S. locations
10
States / cities
Birmingham, Alabama • Los Angeles, California • Indianapolis, Indiana + 7 more
Source: ClinicalTrials.gov public record
Updated Apr 3, 2020 · Synced Oct 25, 2026, 10:33 PM EDT
Not yet recruiting Phase 2 Interventional

Zanubrutinib and Sonrotoclax for the Treatment of Relapsed Chronic Lymphocytic Leukemia /Small Lymphocytic Leukemia, ZeuS-2 Trial

NCT07812246
View directory record Official record
Conditions
Recurrent Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Interventions
Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Computed Tomography, Lymph Node Biopsy, Magnetic Resonance Imaging, Sonrotoclax, Zanubrutinib
Procedure · Drug
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years and older
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2027 – 2028
U.S. locations
3
States / cities
Duarte, California • Irvine, California • Newnan, Georgia
Source: ClinicalTrials.gov public record
Updated Sep 10, 2026 · Synced Oct 25, 2026, 10:33 PM EDT
Recruiting No phase listed Observational

Next Generation Sequencing of Normal Tissues Prospectively in Pediatric Oncology Patients

NCT02530658
View directory record Official record
Conditions
Solid, Liquid, Central Nervous System Tumors
Interventions
Study Introduction Visit, Informed Consent Visit, Informed Consent Follow-Up Visit, Return of Results Conversation, Return of Results Follow-Up Visits, Blood Sample, Skin Biopsy
Other · Procedure
Lead sponsor
St. Jude Children's Research Hospital
Other
Eligibility
Not listed
Enrollment
2,500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2053
U.S. locations
1
States / cities
Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Jul 22, 2026 · Synced Oct 25, 2026, 10:33 PM EDT
Recruiting Phase 2 Interventional

Post-Operative Dosing of Dexamethasone in Patients With Brain Tumors After a Craniotomy, PODS Trial

NCT06132685
View directory record Official record
Conditions
Low Grade Glioma, Malignant Brain Glioma, Malignant Brain Neoplasm, Meningioma
Interventions
Biospecimen Collection, Computed Tomography, Dexamethasone, Magnetic Resonance Imaging, Questionnaire Administration
Procedure · Drug · Other
Lead sponsor
Emory University
Other
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Feb 10, 2026 · Synced Oct 25, 2026, 10:33 PM EDT
Terminated Phase 1 Interventional Results available

Retinoid 9cUAB30 in Producing a Biologic Effect in Patients With Early Stage Breast Cancer

NCT02876640
View directory record Official record
Conditions
Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage IA Breast Cancer AJCC v8, Anatomic Stage IB Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage IIA Breast Cancer AJCC v8, Anatomic Stage IIB Breast Cancer AJCC v8, Breast Ductal Carcinoma In Situ, Early Stage Breast Carcinoma, Invasive Breast Carcinoma
Interventions
Biospecimen Collection, Retinoid 9cUAB30, Therapeutic Conventional Surgery
Procedure · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older · Female only
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
5
States / cities
Birmingham, Alabama • Chicago, Illinois • Iowa City, Iowa + 2 more
Source: ClinicalTrials.gov public record
Updated Jun 18, 2024 · Synced Oct 25, 2026, 10:33 PM EDT
Active, not recruiting Phase 2 Interventional Results available

Testing GDC-0449 (Vismodegib) as Potentially Targeted Treatment in Cancers With Smoothened or Patched 1 Mutant Tumors (MATCH - Subprotocol T)

NCT06357988
View directory record Official record
Conditions
Advanced Lymphoma, Advanced Malignant Solid Neoplasm, Hematopoietic and Lymphatic System Neoplasm, Refractory Lymphoma, Refractory Malignant Solid Neoplasm, Refractory Multiple Myeloma
Interventions
Biopsy Procedure, Biospecimen Collection, Echocardiography Test, Radionuclide Imaging, Vismodegib
Procedure · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2026
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 16, 2026 · Synced Oct 25, 2026, 10:33 PM EDT
Active, not recruiting No phase listed Observational Accepts healthy volunteers

Throat and Other HPV-Related Cancers in Men: Identifying Them Early

NCT02897427
View directory record Official record
Conditions
Human Papillomavirus Infection
Interventions
Biomarker Analysis, Biospecimen Collection, Ultrasonography
Other · Procedure
Lead sponsor
Baylor College of Medicine
Other
Eligibility
50 Years to 64 Years · Male only
Enrollment
1,500 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2027
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jan 26, 2026 · Synced Oct 25, 2026, 10:33 PM EDT
Withdrawn Not applicable Interventional

Vitamin B12 for Aromatase Inhibitors Associated Musculoskeletal Symptoms in Breast Cancer

NCT04205786
View directory record Official record
Conditions
HR-positive Breast Cancer
Interventions
Vitamin B12, Blood collection, Brief Pain Inventory - Short Form survey, FACT-ES Trial Outcome Index (Version 4), Questionnaire to Assess Adherence to Aromatase Inhibitors, Demographics Questionnaire
Dietary Supplement · Other
Lead sponsor
Case Comprehensive Cancer Center
Other
Eligibility
19 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Aug 21, 2024 · Synced Oct 25, 2026, 10:33 PM EDT
Recruiting No phase listed Observational

Examining Blood and Tissue Samples to Identify Diagnostic Markers in Patients With Metastatic Cancer Undergoing Tumor Removal

NCT05530759
View directory record Official record
Conditions
Hematopoietic and Lymphoid System Neoplasm, Metastatic Malignant Solid Neoplasm
Interventions
Biopsy Specimen, Biospecimen Collection, Archived Biospecimen Collection, Medical Chart Review
Procedure · Other
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2031
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jun 9, 2026 · Synced Oct 25, 2026, 10:33 PM EDT
Active, not recruiting Phase 2 Interventional

A Study of a New Drug, Nirogacestat, for Treating Desmoid Tumors That Cannot be Removed by Surgery

NCT04195399
View directory record Official record
Conditions
Desmoid Fibromatosis, Recurrent Desmoid Fibromatosis, Unresectable Desmoid Fibromatosis
Interventions
Biospecimen Collection, Computed Tomography, Echocardiography Test, Magnetic Resonance Imaging, Nirogacestat Hydrobromide, Quality-of-Life Assessment, Questionnaire Administration, X-Ray Imaging
Procedure · Drug · Other
Lead sponsor
Children's Oncology Group
Network
Eligibility
12 Months to 18 Years
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2032
U.S. locations
89
States / cities
Birmingham, Alabama • Mobile, Alabama • Mesa, Arizona + 73 more
Source: ClinicalTrials.gov public record
Updated Oct 1, 2026 · Synced Oct 25, 2026, 10:33 PM EDT
Recruiting Phase 2Phase 3 Interventional

Testing the Addition of Paclitaxel Administered Into the Abdominal Cavity Combined With Chemotherapy for Patients With Gastric Cancer Spread to the Abdominal Cavity

NCT07001748
View directory record Official record
Conditions
Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma, Peritoneal Carcinomatosis
Interventions
Standard of Care Chemotherapy, Biospecimen Collection, Computed Tomography, Diagnostic Laparoscopy, Intraperitoneal Port Placement, Magnetic Resonance Imaging, Intraperitoneal Paclitaxel
Drug · Procedure
Lead sponsor
ECOG-ACRIN Cancer Research Group
Network
Eligibility
18 Years and older
Enrollment
148 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2031
U.S. locations
78
States / cities
Irvine, California • Los Angeles, California • Orange, California + 64 more
Source: ClinicalTrials.gov public record
Updated Oct 5, 2026 · Synced Oct 25, 2026, 10:33 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Improvised Explosive Device (IED) Level Blasting of Human Blood With Slosh Prevention

NCT03018548
View directory record Official record
Conditions
Brain Injuries
Interventions
blood draw
Other
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Aug 24, 2020 · Synced Oct 25, 2026, 10:33 PM EDT
Active, not recruiting Phase 1Phase 2 Interventional

FOLFOX and Bevacizumab in Combination With Botensilimab and Balstilimab (3B-FOLFOX) for the Treatment of Microsatellite Stable (MSS) Metastatic Colorectal Cancer

NCT05627635
View directory record Official record
Conditions
Metastatic Colon Adenocarcinoma, Metastatic Colorectal Adenocarcinoma, Metastatic Microsatellite Stable Colorectal Carcinoma, Metastatic Rectal Adenocarcinoma, Stage IV Colon Cancer AJCC v8, Stage IV Colorectal Cancer AJCC v8, Stage IV Rectal Cancer AJCC v8
Interventions
Balstilimab, Bevacizumab, Biospecimen Collection, Botensilimab, Computed Tomography, Fluorouracil, Leucovorin Calcium, Magnetic Resonance Imaging, Oxaliplatin, Positron Emission Tomography, X-Ray Imaging
Biological · Procedure · Drug
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
Duarte, California
Source: ClinicalTrials.gov public record
Updated Sep 1, 2026 · Synced Oct 25, 2026, 10:33 PM EDT
Recruiting Not applicable Interventional

Cancer Genetic Testing in Ethnic Populations

NCT04475640
View directory record Official record
Conditions
Breast Carcinoma, Carcinoma of Unknown Primary, Central Nervous System Carcinoma, Digestive System Carcinoma, Genitourinary System Carcinoma, Head and Neck Carcinoma, Malignant Brain Neoplasm, Malignant Female Reproductive System Neoplasm, Malignant Musculoskeletal Neoplasm, Malignant Solid Neoplasm, Skin Carcinoma
Interventions
Biospecimen Collection, Genetic Testing
Procedure · Other
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
1,800 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2028
U.S. locations
2
States / cities
Scottsdale, Arizona • Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated Apr 2, 2026 · Synced Oct 25, 2026, 10:33 PM EDT
Recruiting Phase 3 Interventional

Testing Whether the Addition of Carboplatin Chemotherapy to Cabazitaxel Chemotherapy Will Improve Outcomes Compared to Cabazitaxel Alone in People With Castrate-Resistant Prostate Cancer That Has Spread Beyond the Prostate to Other Parts of the Body

NCT06470243
View directory record Official record
Conditions
Castration-Resistant Prostate Carcinoma, Stage IVB Prostate Cancer AJCC v8
Interventions
Biospecimen Collection, Bone Scan, Cabazitaxel, Carboplatin, Chest Radiography, Computed Tomography, Magnetic Resonance Imaging, Positron Emission Tomography, Prednisone
Procedure · Drug
Lead sponsor
SWOG Cancer Research Network
Network
Eligibility
18 Years and older · Male only
Enrollment
528 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2034
U.S. locations
174
States / cities
Fayetteville, Arkansas • Rogers, Arkansas • Springdale, Arkansas + 129 more
Source: ClinicalTrials.gov public record
Updated Jan 22, 2026 · Synced Oct 25, 2026, 10:33 PM EDT
Active, not recruiting Phase 1 Interventional

Testing the Addition of an Immunotherapy Agent, Atezolizumab, When Given With the Usual Chemo-Immunotherapy Drug Combination (Rituximab Plus Gemcitabine and Oxaliplatin) for Relapsed/Refractory (That Has Come Back or Not Responded to Treatment) Transformed Diffuse Large B-Cell Lymphoma

NCT03321643
View directory record Official record
Conditions
Recurrent Diffuse Large B-Cell Lymphoma, Recurrent Transformed Non-Hodgkin Lymphoma, Refractory Diffuse Large B-Cell Lymphoma, Refractory Transformed Non-Hodgkin Lymphoma, Richter Syndrome, Transformed Follicular Lymphoma to Diffuse Large B-Cell Lymphoma
Interventions
Atezolizumab, Biopsy Procedure, Biospecimen Collection, Bone Marrow Biopsy, Computed Tomography, Gemcitabine, Magnetic Resonance Imaging, Oxaliplatin, Positron Emission Tomography, Rituximab
Drug · Procedure · Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2027
U.S. locations
4
States / cities
Duarte, California • La Jolla, California • Sacramento, California + 1 more
Source: ClinicalTrials.gov public record
Updated Jun 11, 2026 · Synced Oct 25, 2026, 10:33 PM EDT